<DOC>
	<DOCNO>NCT00021723</DOCNO>
	<brief_summary>A multi-center , double-blind , placebo-controlled out-patient , safety , tolerability , pilot efficacy study intramuscular AN-1792 patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Randomized Safety , Tolerability Pilot Efficacy AN-1792 Alzheimer 's Disease</brief_title>
	<detailed_description>The study enroll approximately 375 patient mild moderate Alzheimer 's disease investigational site United States Europe . Patients receive either AN-1792 placebo , evaluate use standard clinical assessment cognition memory well experimental surrogate marker Alzheimer 's disease pathology . The goal study evaluate clinical impact elicit immune response ( formation antibody ) A-beta peptide patient Alzheimer 's disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild moderate Alzheimer 's disease . Ability cooperate MRI scan neuropsychological testing . Live home community caregiver capable accompany patient clinic visit visit patient least 5 time per week .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>AN-1792</keyword>
	<keyword>AIP-001</keyword>
</DOC>